VIDEO: Phase 3 clinical trial underway for pterygium eye drop

ByJohn A. Hovanesian, MD, FACS

ByAbu Abraham, MD

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

BOSTON — In this Healio Video Perspective from the ASCRS meeting, Abu Abraham, MD, of Cloudbreak Pharma, and John A. Hovanesian, MD, FACS, discuss developments in the treatment of pterygium.

Abraham previews an eye drop solution, currently in a phase 3 clinical trial, designed to treat pterygium through twice-daily dosing.

“The good news for us is that surgeons who are interested in treating pterygium have effective, modern techniques that work very well,” Hovanesian said. “The other good news for both us and patients is that we have medical therapies that are soon to be, hopefully, available that we can offer that will make surgery not necessary in all cases of pterygium.”

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Abraham reports being the chief medical officer of Cloudbreak Pharma. Hovanesian reports consulting for Cloudbreak Pharma.

Read more

VIDEO: Phase 3 clinical trial underway for pterygium eye drop

Related Content